Brief: Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval For A Phase 1B/2 Clinical Trial Of Soquelitinib
25/06/2025 13:25
June 25 (Reuters) - Corvus Pharmaceuticals Inc CRVS.O: CORVUS PHARMACEUTICALS ANNOUNCES PARTNER ANGEL PHARMACEUTICALS RECEIVED IND APPROVAL FOR A PHASE 1B/2 CLINICAL TRIAL OF SOQUELITINIB IN CHINA FOR THE TREATMENT OF ATOPIC DERMATITIS Source text: ID:nGNX5kV5pT Further company coverage: CRVS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corvus Pharmaceuticals
See all newsBrief: Corvus Pharmaceuticals Announces Initiation Of Phase 1B Clinical Trial Of Soquelitinib For Patients With Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental